{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:38:39Z","timestamp":1792118319732,"version":"4.4.0"},"reference-count":108,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2018,10,2]]},"DOI":"10.1001\/jama.2018.13103","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:12:48Z","timestamp":1538572368000},"page":"1360","source":"Crossref","is-referenced-by-count":2177,"title":["Diagnosis and Management of Rheumatoid Arthritis"],"prefix":"10.1001","volume":"320","author":[{"given":"Daniel","family":"Aletaha","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jrv180007r1","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising? results from Olmsted County, Minnesota, 1955-2007.","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"jrv180007r2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/ard.2010.138693","article-title":"Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction.","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2016-210711","article-title":"Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"76","author":"Chatzidionysiou","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"jrv180007r6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcdb.2015.10.014","article-title":"The cybernetics of TNF: old views and newer ones.","volume":"50","author":"Wallach","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"jrv180007r7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention.","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"jrv180007r8","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1002\/art.30634","article-title":"Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.","volume":"63","author":"Aletaha","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"jrv180007r9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00281-017-0630-4","article-title":"Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.","volume":"39","author":"Viatte","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"9","key":"jrv180007r10","doi-asserted-by":"publisher","first-page":"e1003808","DOI":"10.1371\/journal.pgen.1003808","article-title":"Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.","volume":"9","author":"Scott","year":"2013","journal-title":"PLoS Genet"},{"issue":"10","key":"jrv180007r11","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/art.34539","article-title":"Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis.","volume":"64","author":"Scher","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv180007r12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease.","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"jrv180007r13","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20160792","article-title":"Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.","volume":"213","author":"Tan","year":"2016","journal-title":"J Exp Med"},{"issue":"5","key":"jrv180007r14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins.","volume":"39","author":"Silman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"4","key":"jrv180007r15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/ard.2004.022053","article-title":"Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study.","volume":"64","author":"Stolt","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"jrv180007r16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"2","key":"jrv180007r17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/BOR.0b013e328336474d","article-title":"Recent advances in the genetics of rheumatoid arthritis.","volume":"22","author":"Raychaudhuri","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"jrv180007r18","doi-asserted-by":"publisher","first-page":"e01202","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"issue":"9","key":"jrv180007r19","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1002\/art.27552","article-title":"Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and a-enolase: implications for autoimmunity in rheumatoid arthritis.","volume":"62","author":"Wegner","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6380","key":"jrv180007r20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aar7201","article-title":"Translocation of a gut pathobiont drives autoimmunity in mice and humans.","volume":"359","author":"Manfredo Vieira","year":"2018","journal-title":"Science"},{"issue":"8","key":"jrv180007r21","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1172\/JCI93450","article-title":"Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints.","volume":"127","author":"Pianta","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"jrv180007r22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4110\/in.2014.14.1.7","article-title":"Potential role of bacterial infection in autoimmune diseases: a new aspect of molecular mimicry.","volume":"14","author":"Alam","year":"2014","journal-title":"Immune Netw"},{"issue":"5","key":"jrv180007r23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity.","volume":"50","author":"Harley","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"jrv180007r24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00281-017-0621-5","article-title":"Epigenetics in the pathogenesis of RA.","volume":"39","author":"Ospelt","year":"2017","journal-title":"Semin Immunopathol"},{"key":"jrv180007r25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13075-015-0736-9","article-title":"Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.","volume":"17","author":"Aletaha","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"jrv180007r26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis.","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"jrv180007r27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"jrv180007r28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.v66.3","article-title":"Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis.","volume":"66","author":"de Hair","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"jrv180007r29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv180007r30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r31","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"jrv180007r32","first-page":"1681","article-title":"Work disability in rheumatoid arthritis 10 years after the diagnosis.","volume":"26","author":"Sokka","year":"1999","journal-title":"J Rheumatol"},{"key":"jrv180007r33","first-page":"13","article-title":"The natural history of rheumatoid arthritis.","volume":"44","author":"Wolfe","year":"1996","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"jrv180007r34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis.","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"jrv180007r35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/rheumatology\/keq334","article-title":"Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis.","volume":"50","author":"Radner","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"jrv180007r36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/ard.2007.071415","article-title":"Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results.","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"jrv180007r37","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/annrheumdis-2013-203284","article-title":"Performance of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: a systematic literature review.","volume":"73","author":"Radner","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"jrv180007r39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.v67.7","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"jrv180007r40","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"jrv180007r41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/ard.61.4.290","article-title":"Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.","volume":"61","author":"Emery","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv180007r42","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"jrv180007r43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients.","volume":"31","author":"van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"3","key":"jrv180007r44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv180007r45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"jrv180007r46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/annrheumdis-2015-208324","article-title":"Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point.","volume":"75","author":"Aletaha","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"jrv180007r47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","article-title":"Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.","volume":"75","author":"Dale","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2015-209057","article-title":"Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-na\u00efve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9149","key":"jrv180007r51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"jrv180007r52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"9865","key":"jrv180007r53","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"jrv180007r54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"jrv180007r55","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis.","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"9685","key":"jrv180007r56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"issue":"9617","key":"jrv180007r57","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"jrv180007r58","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv180007r59","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"jrv180007r60","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"jrv180007r61","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"issue":"11","key":"jrv180007r62","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv180007r63","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.","volume":"77","author":"Kay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6A","key":"jrv180007r65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9343(83)90477-1","article-title":"Methotrexate therapy in rheumatoid arthritis: 15 years experience.","volume":"75","author":"Hoffmeister","year":"1983","journal-title":"Am J Med"},{"issue":"7","key":"jrv180007r66","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv180007r67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8688","key":"jrv180007r68","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0140-6736(90)90771-V","article-title":"Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.","volume":"335","author":"van der Heijde","year":"1990","journal-title":"Lancet"},{"issue":"6","key":"jrv180007r69","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"jrv180007r71","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"jrv180007r72","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/rheumatology\/keq406","article-title":"Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity\u2014the early RA network (ERAN).","volume":"50","author":"Kiely","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"10061","key":"jrv180007r73","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"jrv180007r74","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24?months, with a 12-month, double-blind treatment period.","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"jrv180007r76","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10093","key":"jrv180007r77","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial.","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"9877","key":"jrv180007r78","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"jrv180007r79","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"jrv180007r80","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis.","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"jrv180007r81","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis.","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"10139","key":"jrv180007r82","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"10139","key":"jrv180007r83","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"jrv180007r84","doi-asserted-by":"crossref","first-page":"A67","DOI":"10.1136\/annrheumdis-2018-eular.4237","article-title":"Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r85","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv180007r86","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"jrv180007r87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/(ISSN)2326-5205","article-title":"Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.","volume":"66","author":"Ducreux","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"jrv180007r88","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"jrv180007r89","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"jrv180007r90","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/art.37797","article-title":"Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.","volume":"65","author":"Binder","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"jrv180007r91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-017-1484-9","article-title":"Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.","volume":"20","author":"Smolen","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"9870","key":"jrv180007r92","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"jrv180007r93","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jrv180007r94","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"jrv180007r95","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"jrv180007r96","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/(ISSN)1529-0131","article-title":"A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.","volume":"38","author":"van der Lubbe","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"jrv180007r97","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv180007r98","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3899\/jrheum.100602","article-title":"A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.","volume":"38","author":"Genovese","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"jrv180007r100","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.","volume":"74","author":"Aga","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv180007r101","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab.","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv180007r102","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries.","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jrv180007r103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis?","volume":"39","author":"Cheung","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"5","key":"jrv180007r104","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.v70.5","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor a monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis.","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"jrv180007r105","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-015-0742-y","article-title":"Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis.","volume":"17","author":"Bl\u00fcml","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"jrv180007r106","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clim.2017.08.009","article-title":"The unmet need in rheumatology: reports from the targeted therapies meeting 2017.","volume":"186","author":"Winthrop","year":"2018","journal-title":"Clin Immunol"},{"issue":"5","key":"jrv180007r107","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","article-title":"EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.","volume":"71","author":"Gerlag","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"jrv180007r108","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/art.40061","article-title":"Prevention of rheumatoid arthritis: now is the time, but how to proceed?","volume":"69","author":"Deane","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"jrv180007r99","unstructured":"National Assembly (Parliament). Bundesgesetz, mit dem das Allgemeine Sozialversicherungsgesetz ge\u00e4ndert wird (Amendment of the Social Security Law). https:\/\/www.parlament.gv.at\/PAKT\/VHG\/XXV\/BNR\/BNR_00472\/fnameorig_626979.html. 2018. Accessed August 30, 2018."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2705192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:29:19Z","timestamp":1761110959000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2018.13103"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2018,10,2]]},"references-count":108,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,10,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2018.13103","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734156934.793564291","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,2]]}}}